New York, Jan 7, 2026, 10:56 EST — Regular session
Regencell Bioscience Holdings Limited shares jumped about 27% to $41.90 in morning trading on Wednesday, extending a sharp two-day run for the Nasdaq-listed microcap. The stock has swung between $34.11 and $43.74 so far in the session, with nearly 1.0 million shares traded.
Why it matters now: the move builds on Tuesday’s 22% gain and keeps Regencell near the top of the day’s high-volatility names, even by small-cap standards. The stock closed at $33.03 on Tuesday after trading as high as $35.68, following a $27.00 close on Monday.
The rally has come alongside unusually heavy turnover. TipRanks said about 1.4 million Regencell shares traded on Tuesday versus an average volume of roughly 249,000 shares, and it flagged no company-specific headline tied to the surge.
That kind of tape can feed on itself. Nasdaq data show Regencell has traded between $0.09 and $83.60 over the last 52 weeks, a range that leaves little room for calm positioning when buyers show up in size.
Short interest — shares borrowed and sold by traders betting on a drop — looked modest heading into the week. Yahoo Finance data show 1.21 million shares sold short as of Dec. 15, about 2.19% of float (the shares readily available to trade), with a short ratio of 5.67 days.
Regencell describes itself as a bioscience company focused on research and development of traditional Chinese medicine for neurocognitive disorders, including attention deficit hyperactivity disorder and autism spectrum disorder.
But the fundamentals leave plenty of room for doubt if the stock’s spotlight fades. In its annual report for the fiscal year ended June 30, 2025, the company said it had no saleable products and had not generated revenue from product sales, and it reported net losses of $3.58 million in fiscal 2025 and $4.36 million in fiscal 2024.
